| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | Deep Track Capital, LP | ALBIREO PHARMA, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-04-10 | FEDERATED HERMES, INC. | ALBIREO PHARMA, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-03-08 | BlackRock Inc. | ALBIREO PHARMA, INC. | 506,425 | 2.4% | EDGAR |
| SC 13G | 2023-03-02 | ICS OPPORTUNITIES, LTD. | ALBIREO PHARMA, INC. | 893,869 | 4.3% | EDGAR |
| SC 13G | 2023-02-27 | Beryl Capital Management LLC | ALBIREO PHARMA, INC. | 1,483,599 | 7.1% | EDGAR |
| SC 13G | 2023-02-24 | CARLSON CAPITAL L P | ALBIREO PHARMA, INC. | 178,146 | 1.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | ALBIREO PHARMA, INC. | 1,704,000 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-14 | PERCEPTIVE ADVISORS LLC | ALBIREO PHARMA, INC. | 1,757,160 | 8.5% | EDGAR |
| SC 13G/A | 2023-02-14 | TANG CAPITAL PARTNERS LP | ALBIREO PHARMA, INC. | 411,968 | 2.0% | EDGAR |
| SC 13G/A | 2023-02-01 | STATE STREET CORP | ALBIREO PHARMA, INC. | - | 1.7% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | ALBIREO PHARMA, INC. | 1,344,897 | 6.5% | EDGAR |
| SC 13G/A | 2023-02-01 | FEDERATED HERMES, INC. | ALBIREO PHARMA, INC. | 1,956,488 | 9.4% | EDGAR |
| SC 13G | 2023-01-23 | Chicago Capital, LLC | ALBIREO PHARMA, INC. | 1,362,484 | 6.6% | EDGAR |
| SC 13G | 2022-10-03 | Deep Track Capital, LP | ALBIREO PHARMA, INC. | 1,124,421 | 5.5% | EDGAR |
| SC 13G | 2022-09-26 | TANG CAPITAL PARTNERS LP | ALBIREO PHARMA, INC. | 1,099,516 | 5.6% | EDGAR |
| SC 13G | 2022-03-07 | Chicago Capital, LLC | ALBIREO PHARMA, INC. | 971,885 | 5.1% | EDGAR |
| SC 13G/A | 2022-02-14 | PERCEPTIVE ADVISORS LLC | ALBIREO PHARMA, INC. | 2,360,139 | 12.2% | EDGAR |
| SC 13G/A | 2022-02-14 | FEDERATED HERMES, INC. | ALBIREO PHARMA, INC. | 2,358,624 | 12.2% | EDGAR |
| SC 13G | 2022-02-09 | STATE STREET CORP | ALBIREO PHARMA, INC. | - | 5.2% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | ALBIREO PHARMA, INC. | 1,168,783 | 6.1% | EDGAR |